Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Not Yet Opened 09-29 16:00:00 EDT

13.00

+0.44

+3.50%

盘后13.10

+0.10+0.77%

19:59 EDT

High13.42	Low12.35	Vol4.37M
Open12.44	D1 Closing12.56	Amplitude8.52%
Mkt Cap1.22B	Tradable Cap1.01B	Total Shares94.22M
T/O57.02M	T/O Rate5.63%	Tradable Shares77.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":13,"timestamp":1790712000000,"preClose":12.56,"halted":0,"volume":4365283,"hourTrading":{"tag":"盘后","latestPrice":13.1,"preClose":13,"latestTime":"19:59 EDT","volume":37441,"amount":486740.78,"timestamp":1790726357261,"change":0.1,"changeRate":0.007692,"amplitude":0.007692},"delay":0,"changeRate":0.03503184713375792,"floatShares":77485633,"shares":94219634,"eps":-3.154987,"marketStatus":"Not Yet Opened","change":0.44,"latestTime":"09-29 16:00:00 EDT","open":12.44,"high":13.42,"low":12.35,"amount":57019653.942225,"amplitude":0.085191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.154987,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790755200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":12.56,"preHourTrading":{"tag":"盘前","latestPrice":12.48,"preClose":12.56,"latestTime":"09:29 EDT","volume":2400,"amount":30115.1424,"timestamp":1790688570040,"change":-0.08,"changeRate":-0.006369,"amplitude":0.015127},"postHourTrading":{"tag":"盘后","latestPrice":13.1,"preClose":13,"latestTime":"19:59 EDT","volume":37441,"amount":486740.78,"timestamp":1790726357261,"change":0.1,"changeRate":0.007692,"amplitude":0.007692},"volumeRatio":2.270434,"impliedVol":1.1816,"impliedVolPercentile":0.484},"requestUrl":"/m/hq/s/REPL/wiki","defaultTab":"wiki","newsList":[{"id":"2671724622","title":"How More Share Capacity Will Impact Replimune Group (REPL) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2671724622","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671724622?lang=en_us&edition=fundamental","pubTime":"2026-09-29 22:23","pubTimestamp":1790691790,"startTime":"0","endTime":"0","summary":"Replimune Group stockholders approved an amendment to the Third Amended and Restated Certificate of Incorporation that raised authorized common shares from 150,000,000 to 300,000,000, with the change becoming effective upon filing in Delaware on September 15, 2026.\nThe sharp increase in authorized equity gives Replimune Group more room to issue new shares, which can influence future capital raising choices, acquisition currency, and employee equity programs, as well as potential dilution...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/how-more-share-capacity-will-impact-replimune-group-repl-inv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/how-more-share-capacity-will-impact-replimune-group-repl-inv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK4139","REPL","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933155","title":"Replimune Group - Approves Amendment to Increase Authorized Common Shares to 300,000,000 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933155?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:06","pubTimestamp":1789589214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668161933","title":"Replimune Holds Annual Shareholder Meeting, Backs Authorized Common Share Increase to 300 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2668161933","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668161933?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:06","pubTimestamp":1789589200,"startTime":"0","endTime":"0","summary":"Replimune holds annual shareholder meeting, backs authorized common share increase to 300 millionReplimune held its annual shareholder meeting on Sept. 15, 2026.Shareholders ratified PricewaterhouseCo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDLMMxgs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Replimune Holds Annual Shareholder Meeting, Backs Authorized Common Share Increase to 300 Million","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877182","title":"Replimune to Present at the Cantor Global Healthcare Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877182","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877182?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436800,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., Sept.  03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355852/0/en/replimune-to-present-at-the-cantor-global-healthcare-conference-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","HCSG","REPL","BK4585","LU0128526141.USD","XBI","BK4139","BK4137","BK4588","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662120082","title":"Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2662120082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662120082?lang=en_us&edition=fundamental","pubTime":"2026-08-28 01:35","pubTimestamp":1787852158,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) and several current or former company leaders have asked a federal court in Massachusetts to dismiss an invest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-company-asks-court-to-dismiss-securities-case-over-rp1-fda-approval-process?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-company-asks-court-to-dismiss-securities-case-over-rp1-fda-approval-process?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPIQ","NVIW.SI","BK4585","QQQM","QYLG","BK4588","PSQ","LABU","TQQQ","JEPQ","BK4139","IYW","QDTE","TQQY","QLD","QQQE","REPL","FTEC","QQQA","QQQY","QQQJ","QQQ","SQQQ","NQmain","NDX","MNQmain","QID","ONEQ","TECS",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661292264","title":"Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2661292264","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661292264?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:13","pubTimestamp":1787339620,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts about regulatory weakne...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQJ","GPIQ","TQQQ","QLD","QYLG","LABU","NDX","FTEC","MNQmain","TECS",".IXIC","PSQ","QID","BK4585","QDTE","BK4139","ONEQ","TQQY","QQQ","SQQQ","QQQY","NVIW.SI","BK4588","QQQM","QQQA","REPL","JEPQ","IYW","QQQE","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407478","title":"Replimune Grants CCO Michelle DiNapoli Options for 150,000 Shares at $15.58, Plus 100,000 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407478","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407478?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:01","pubTimestamp":1787169675,"startTime":"0","endTime":"0","summary":"Replimune grants CCO Michelle DiNapoli options for 150,000 shares at $15.58, plus 100,000 RSUsReplimune set inducement equity awards for Chief Commercial Officer Michelle DiNapoli: options for 150,000","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL5VVRyw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B3QW5Z07.USD","NDAQ","REPL","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","BK4585","BK4588","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BQXX3C00.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478283","title":"Press Release: Replimune Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478283","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478283?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:01","pubTimestamp":1787169660,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ann","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain",".IXIC","PSQ","QQQE","SQQQ","BK4139","QDTE","TQQQ","MNQmain","QQQM","QQQA","QID","QQQY","QQQ","QLD","IYW","QYLG","REPL","NDX","FTEC","GPIQ","QQQJ","JEPQ","ONEQ","NVIW.SI","TECS","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660413569","title":"Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660413569","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660413569?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:35","pubTimestamp":1787099724,"startTime":"0","endTime":"0","summary":"UPDATE 3-Trump picks White House adviser Heidi Overton to run FDA, source saysAug 18 (Reuters)-U.S. President Donald Trump has chosen White House policy aide Heidi Overton to lead the Food and Drug Ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL6N44G00Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","MRNX","MRNA","REPL","BK4548","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","BK4501","BK4563","BK4568","SRPU","IDNA","IE0009355771.USD","GNOM","BK4585","IE00BJT1NW94.SGD","BK4588","WDNA","BK4532","BK4139","MRNY","BK4551","LGHT","BK4534","SRPT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494146","title":"Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494146","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494146?lang=en_us&edition=fundamental","pubTime":"2026-08-19 03:29","pubTimestamp":1787081359,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that investors were not told key facts about regulatory weakne...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-focuses-on-fda-disclosure-issues-and-sharp-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","JEPQ","BK4139","ONEQ","GPIQ","QQQ","QQQY","QDTE","TECS","QQQA","QQQJ","BK4588","LABU","QQQM","QID","NDX","QQQE","NVIW.SI","TQQQ","FTEC","SQQQ","QYLG",".IXIC","QLD","MNQmain","REPL","BK4585","TQQY","NQmain","IYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436614","title":"Jefferies Remains a Buy on Replimune Group (REPL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660436614?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:15","pubTimestamp":1786979742,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Replimune Group, with a price target of $24.00. Song covers the He...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-replimune-group-repl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-replimune-group-repl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659172475","title":"Replimune files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2659172475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659172475?lang=en_us&edition=fundamental","pubTime":"2026-08-16 20:38","pubTimestamp":1786883912,"startTime":"0","endTime":"0","summary":"16:53 EDT Replimune (REPL) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121931","title":"Replimune Group, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121931","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121931?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:53","pubTimestamp":1786740803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B2BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126569","title":"Replimune Group Lawsuit Alleges Investors Were Misled Before REPL Stock Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126569","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126569?lang=en_us&edition=fundamental","pubTime":"2026-08-15 03:16","pubTimestamp":1786734977,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. (NASDAQ: REPL) is facing a federal securities lawsuit alleging that the company misled investors about the regulatory strengt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-alleges-investors-were-misled-before-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/replimune-group-lawsuit-alleges-investors-were-misled-before-repl-stock-drop?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","FTEC","IYW","QQQY","SQQQ","TECS","QID","QQQE","GPIQ","JEPQ","QYLG","ONEQ","QQQ","QLD","BK4211","NQmain","QDTE","MNQmain","BK4139","PSQ","ISBC","QQQM","REPL","QQQA","NVIW.SI",".IXIC","NDX","TQQQ","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659415291","title":"Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659415291","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659415291?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711203,"startTime":"0","endTime":"0","summary":"BRIEF-Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate UpdateAug 14 (Reuters)-Replimune Group, Inc.REPL.O:REPLIMUNE REPORTS FISCAL FIRST QUARTER 2027 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESource text:ID:nGNX4b8z5dFurther company coverage:REPL.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUABPJTYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149626","title":"Replimune Q1 Net Loss Narrows as Expenses Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149626","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149626?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:14","pubTimestamp":1786709664,"startTime":"0","endTime":"0","summary":"Replimune Q1 net loss narrows as expenses declineOverviewUS oncolytic immunotherapy firm's fiscal Q1 net loss narrowed year-over-yearCompany received FDA accelerated approval for TUDRIQEV in advanced ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","CRDF","BK4139","REPL","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659304149","title":"Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2659304149","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659304149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:09","pubTimestamp":1786709343,"startTime":"0","endTime":"0","summary":"Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149316","title":"Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149316","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149316?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:06","pubTimestamp":1786709186,"startTime":"0","endTime":"0","summary":"Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61205474/replimune-group-q1-eps-0-72-beats-0-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146057","title":"Replimune FY27 Q1 Net Loss Narrows to $69.8 Million; R&D Expenses Fall to $49.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146057","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146057?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:02","pubTimestamp":1786708955,"startTime":"0","endTime":"0","summary":"Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 millionReplimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL8DSTHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014013.SGD","SG9999014039.USD","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","BK4139","LU2210150020.SGD","BK4112","BCDF","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","REPL","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659467691","title":"Replimune Group Q1 EPS USD -0.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2659467691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659467691?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:01","pubTimestamp":1786708911,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLX9PV7WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com;ir.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.1613},{"period":"3month","weight":0.1586},{"period":"6month","weight":0.5458},{"period":"1year","weight":1.9954},{"period":"ytd","weight":0.3374}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.229422},{"month":7,"riseRate":0.375,"avgChangeRate":-0.075914},{"month":8,"riseRate":0.444444,"avgChangeRate":0.06155},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.065905},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}